Literature DB >> 17216458

A rare sugar xylitol. Part II: biotechnological production and future applications of xylitol.

Tom Birger Granström1, Ken Izumori, Matti Leisola.   

Abstract

Xylitol is the first rare sugar that has global markets. It has beneficial health properties and represents an alternative to current conventional sweeteners. Industrially, xylitol is produced by chemical hydrogenation of D-xylose into xylitol. The biotechnological method of producing xylitol by metabolically engineered yeasts, Saccharomyces cerevisiae or Candida, has been studied as an alternative to the chemical method. Due to the industrial scale of production, xylitol serves as an inexpensive starting material for the production of other rare sugars. The second part of this mini-review on xylitol will look more closely at the biotechnological production and future applications of the rare sugar, xylitol.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17216458     DOI: 10.1007/s00253-006-0760-4

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   4.813


  25 in total

1.  Characterization of the sugar alcohol-producing yeast Pichia anomala.

Authors:  Guoqiang Zhang; Yuping Lin; Peng He; Lin Li; Qinhong Wang; Yanhe Ma
Journal:  J Ind Microbiol Biotechnol       Date:  2013-10-30       Impact factor: 3.346

2.  Novel endophytic yeast Rhodotorula mucilaginosa strain PTD3 I: production of xylitol and ethanol.

Authors:  Renata Bura; Azra Vajzovic; Sharon L Doty
Journal:  J Ind Microbiol Biotechnol       Date:  2012-03-08       Impact factor: 3.346

3.  Continuous co-production of ethanol and xylitol from rice straw hydrolysate in a membrane bioreactor.

Authors:  Omid Zahed; Gholamreza Salehi Jouzani; Saeed Abbasalizadeh; Faramarz Khodaiyan; Meisam Tabatabaei
Journal:  Folia Microbiol (Praha)       Date:  2015-09-09       Impact factor: 2.099

4.  Combined treatment of Pseudomonas aeruginosa biofilm with lactoferrin and xylitol inhibits the ability of bacteria to respond to damage resulting from lactoferrin iron chelation.

Authors:  Mary Cloud B Ammons; Loren S Ward; Scot Dowd; Garth A James
Journal:  Int J Antimicrob Agents       Date:  2011-03-05       Impact factor: 5.283

5.  Directed evolution as a powerful synthetic biology tool.

Authors:  Ryan E Cobb; Ning Sun; Huimin Zhao
Journal:  Methods       Date:  2012-03-23       Impact factor: 3.608

6.  Two-step enzymatic synthesis of 6-deoxy-L-psicose.

Authors:  Liuqing Wen; Kenneth Huang; Yuan Zheng; Junqiang Fang; Shukkoor Muhammed Kondengaden; Peng George Wang
Journal:  Tetrahedron Lett       Date:  2016-07-06       Impact factor: 2.415

7.  In vitro susceptibility of established biofilms composed of a clinical wound isolate of Pseudomonas aeruginosa treated with lactoferrin and xylitol.

Authors:  Mary Cloud B Ammons; Loren S Ward; Steve T Fisher; Randall D Wolcott; Garth A James
Journal:  Int J Antimicrob Agents       Date:  2008-11-01       Impact factor: 5.283

Review 8.  Progress in metabolic engineering of Saccharomyces cerevisiae.

Authors:  Elke Nevoigt
Journal:  Microbiol Mol Biol Rev       Date:  2008-09       Impact factor: 11.056

Review 9.  Anti-biofilm strategies and the need for innovations in wound care.

Authors:  Mary C B Ammons
Journal:  Recent Pat Antiinfect Drug Discov       Date:  2010-01

Review 10.  Mini-review: Lactoferrin: a bioinspired, anti-biofilm therapeutic.

Authors:  M C Ammons; V Copié
Journal:  Biofouling       Date:  2013       Impact factor: 3.209

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.